| Autor: |
Wang, Yang, Li, Qiqi, Li, Cheng, Wang, Cong, Wang, Shijie, Yuan, Wenjie, Yu, Demin, Zhang, Ke, Shi, Bisheng, Chen, Xiaomei, Liu, Tiantian, Yuan, Zhenghong, Tong, Shuping, Nassal, Michael, Wen, Yu-Mei, Wang, Yong-Xiang |
| Zdroj: |
Gut; 2024, Vol. 73 Issue: 4 p668-681, 14p |
| Abstrakt: |
ObjectivesChronic hepatitis B (CHB) caused by HBV infection greatly increases the risk of liver cirrhosis and hepatocellular carcinoma. Hepatitis B surface antigen (HBsAg) plays critical roles in the pathogenesis of CHB. HBsAg loss is the key indicator for cure of CHB, but is rarely achieved by current approved anti-HBV drugs. Therefore, novel anti-HBV strategies are urgently needed to achieve sustained HBsAg loss.DesignWe developed multiple chimeric antigen receptors (CARs) based on single-chain variable fragments (scFvs, namely MA18/7-scFv and G12-scFv), respectively, targeting HBV large and small envelope proteins. Their impacts on HBsAg secretion and HBV infection, and the underlying mechanisms, were extensively investigated using various cell culture models and HBV mouse models.ResultsAfter secretory signal peptide mediated translocation into endoplasmic reticulum (ER) and secretory pathway, MA18/7-scFv and CARs blocked HBV infection and virion secretion. G12-scFv preferentially inhibited virion secretion, while both its CAR formats and crystallisable fragment (Fc)-attached versions blocked HBsAg secretion. G12-scFv and G12-CAR arrested HBV envelope proteins mainly in ER and potently inhibited HBV budding. Furthermore, G12-scFv-Fc and G12-CAR-Fc strongly suppressed serum HBsAg up to 130-fold in HBV mouse models. The inhibitory effect lasted for at least 8 weeks when delivered by an adeno-associated virus vector.ConclusionCARs possess direct antiviral activity, besides the well-known application in T-cell therapy. Fc attached G12-scFv and G12-CARs could provide a novel approach for reducing circulating HBsAg. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
